1-11 of 11
Jhanelle E. Gray
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)

Shirish M. Gadgeel, Jieling Miao, Jonathan W. Riess, James Moon, Philip C. Mack, Gregory J. Gerstner, Timothy F. Burns, Asma Taj, Wallace L. Akerley, III, Konstantin H. Dragnev, Noel Laudi, Mary W. Redman, Jhanelle E. Gray, David R. Gandara, Karen Kelly
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18): 3641–3649.
https://doi.org/10.1158/1078-0432.CCR-22-3947
Published: 15 September 2023
View article titled, Phase II Study of Docetaxel and Trametinib in Patients with <em>KRAS</em> Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Open the PDF for Phase II Study of Docetaxel and Trametinib in Patients with <em>KRAS</em> Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042) in another window
Includes: Supplementary data
Journal Articles

Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

Jhanelle E. Gray, Myung-Ju Ahn, Geoffrey R. Oxnard, Frances A. Shepherd, Fumio Imamura, Ying Cheng, Isamu Okamoto, Byoung Chul Cho, Meng-Chih Lin, Yi-Long Wu, Margarita Majem, Oliver Gautschi, Michael Boyer, Krishna C. Bulusu, Aleksandra Markovets, J. Carl Barrett, Rachel Hodge, Astrid McKeown, Ryan J. Hartmaier, Juliann Chmielecki, Vassiliki A. Papadimitrakopoulou, Suresh S. Ramalingam
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3340–3351.
https://doi.org/10.1158/1078-0432.CCR-22-3146
Published: 01 September 2023
View article titled, Early Clearance of Plasma <em>Epidermal Growth Factor Receptor</em> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
Open the PDF for Early Clearance of Plasma <em>Epidermal Growth Factor Receptor</em> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

Martin H. Voss, Arun A. Azad, Aaron R. Hansen, Jhanelle E. Gray, Sarah J. Welsh, Xuyang Song, Michael Kuziora, Lina Meinecke, Jorge Blando, Ikbel Achour, Yi Wang, Farzana L. Walcott, Sjoukje F. Oosting
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (14): 3032–3041.
https://doi.org/10.1158/1078-0432.CCR-21-4115
Published: 15 July 2022
View article titled, A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma
Open the PDF for A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

Alberto A. Chiappori, Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, Ram Thapa, Margaret L. Barlow, Zhihua Chen, Dung Tsa Chen, Amer A. Beg, Theresa A. Boyle, Julio Castro, Liza Morgan, Erick Morris, Mehreteab Aregay, Felipe K. Hurtado, Luigi Manenti, Scott Antonia
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (11): 2313–2320.
https://doi.org/10.1158/1078-0432.CCR-21-2742
Published: 01 June 2022
View article titled, Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer
Open the PDF for Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract PR-03: Radiomics and AI-based treatment decision support for non-small cell lung cancer

Wei Mu, Lei Jiang, Jianyuan Zhang, Yu Shi, Jhanelle E. Gray, Xinming Zhao, Xilin Sun, Jie Tian, Matthew B. Schabath, Robert J. Gillies
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5_Supplement): PR-03.
https://doi.org/10.1158/1557-3265.ADI21-PR-03
Published: 01 March 2021
View article titled, Abstract PR-03: Radiomics and AI-based treatment decision support for non-small cell lung cancer
Journal Articles

Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

Jhanelle E. Gray, Andreas Saltos, Tawee Tanvetyanon, Eric B. Haura, Ben Creelan, Scott J. Antonia, Michael Shafique, Hong Zheng, Wenjie Dai, James J. Saller, Zhihua Chen, Nishan Tchekmedyian, Kristen Goas, Ram Thapa, Theresa A. Boyle, Dung-Tsa Chen, Amer A. Beg
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22): 6623–6632.
https://doi.org/10.1158/1078-0432.CCR-19-1305
Published: 15 November 2019
View article titled, Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer
Open the PDF for Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Jhanelle E. Gray, Isamu Okamoto, Virote Sriuranpong, Johan Vansteenkiste, Fumio Imamura, Jong Seok Lee, Yong-Kek Pang, Manuel Cobo, Kazuo Kasahara, Ying Cheng, Naoyuki Nogami, Eun Kyung Cho, Wu Chou Su, Guili Zhang, Xiangning Huang, Xiaocheng Li-Sucholeiki, Brian Lentrichia, Simon Dearden, Suzanne Jenkins, Matilde Saggese, Yuri Rukazenkov, Suresh S. Ramalingam
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22): 6644–6652.
https://doi.org/10.1158/1078-0432.CCR-19-1126
Published: 15 November 2019
View article titled, Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Open the PDF for Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non–Small Cell Lung Cancer

David Planchard, Michael J. Boyer, Jong-Seok Lee, Arunee Dechaphunkul, Parneet K. Cheema, Toshiaki Takahashi, Jhanelle E. Gray, Marcello Tiseo, Suresh S. Ramalingam, Alexander Todd, Astrid McKeown, Yuri Rukazenkov, Yuichiro Ohe
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2058–2063.
https://doi.org/10.1158/1078-0432.CCR-18-3325
Published: 01 April 2019
View article titled, Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non–Small Cell Lung Cancer
Open the PDF for Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non–Small Cell Lung Cancer in another window
Journal Articles

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC

Xiuning Le, Sonam Puri, Marcelo V. Negrao, Monique B. Nilsson, Jacqulyne Robichaux, Theresa Boyle, J. Kevin Hicks, Katherine L. Lovinger, Emily Roarty, Waree Rinsurongkawong, Ming Tang, Huiying Sun, Yasir Elamin, Lara C. Lacerda, Jeff Lewis, Jack A. Roth, Stephen G. Swisher, J. Jack Lee, William N. William, Jr, Bonnie S. Glisson, Jianjun Zhang, Vassiliki A. Papadimitrakopoulou, Jhanelle E. Gray, John V. Heymach
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (24): 6195–6203.
https://doi.org/10.1158/1078-0432.CCR-18-1542
Published: 13 December 2018
View article titled, Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <em>EGFR</em>-Mutant NSCLC
Open the PDF for Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <em>EGFR</em>-Mutant NSCLC in another window
Includes: Supplementary data
Journal Articles

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

Jhanelle E. Gray, Rebecca S. Heist, Alexander N. Starodub, D. Ross Camidge, Ebenezer A. Kio, Gregory A. Masters, W. Thomas Purcell, Michael J. Guarino, Jamal Misleh, Charles J. Schneider, Bryan J. Schneider, Allyson Ocean, Tirrell Johnson, Leena Gandhi, Kevin Kalinsky, Ronald Scheff, Wells A. Messersmith, Serengulam V. Govindan, Pius P. Maliakal, Boyd Mudenda, William A. Wegener, Robert M. Sharkey, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (19): 5711–5719.
https://doi.org/10.1158/1078-0432.CCR-17-0933
Published: 01 October 2017
View article titled, Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
Open the PDF for Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan in another window
Includes: Supplementary data
Journal Articles

A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors

Jhanelle E. Gray, Eric Haura, Alberto Chiappori, Tawee Tanvetyanon, Charles C. Williams, Mary Pinder-Schenck, Julie A. Kish, Jenny Kreahling, Richard Lush, Anthony Neuger, Leticia Tetteh, Angela Akar, Xiuhua Zhao, Michael J. Schell, Gerold Bepler, Soner Altiok
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (6): 1644–1655.
https://doi.org/10.1158/1078-0432.CCR-13-2235
Published: 13 March 2014
View article titled, A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors
Open the PDF for A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors in another window